Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RA0118
- Development stage
- Preclinical
- Lead developer
- Remab Therapeutics
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
RA0118 is a preclinical-stage polymeric glycoconjugate being developed by Remab Therapeutics for the treatment of alpha-gal syndrome (red meat allergy) and the prevention of allergic reactions to monoclonal antibody therapies containing the alpha-gal epitope. The drug consists of a poly-L-lysine backbone (DP1000) with approximately 18% of its lysine residues derivatized with the Gal-alpha-1,3-Gal-beta-1,4-GlcNAc (alpha-gal) epitope. RA0118 functions by selectively binding to and removing circulating anti-alpha-gal IgE antibodies, which are responsible for hypersensitivity reactions in sensitized individuals. By depleting these harmful antibodies, the therapy aims to prevent anaphylaxis and other allergic symptoms triggered by exposure to alpha-gal.
- Other names
- poly-L-lysine-based alpha-Gal-glycoconjugate
02
Targets
Anti-alpha-galactosyl immunoglobulin A antibodiesα-Gal-specific IgE (Galactose-α-1,3-galactose-specific IgE)Anti-galactose-alpha-1,3-galactose immunoglobulin GAnti-galactose-alpha-1,3-galactose immunoglobulin M antibody
Beyond the preview
Go deeper on RA0118.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RA0118.